For a patient with gastro‑oesophageal reflux disease (GERD) treated with domperidone and famotidine, what is the recommended duration of therapy for each medication?

Duration of Domperidone and Famotidine Therapy in GERD

For GERD treatment, famotidine should be used for 4-8 weeks initially, with reassessment at 12 months if continued, while domperidone is not recommended as it lacks evidence for efficacy in GERD and carries significant safety concerns.

Famotidine Duration

Initial Treatment Course

• Start with a 4-8 week trial of famotidine for symptomatic GERD without alarm features 1
• For erosive esophagitis, famotidine trials have demonstrated safety and efficacy up to 12 weeks maximum 2
• FDA labeling explicitly states: "Trials have not assessed the safety of Famotidine in uncomplicated active [ulcer disease] for periods of more than 8 weeks" 2

Long-term Management Strategy

• If symptoms resolve, taper to the lowest effective dose or convert to on-demand therapy 1
• If therapy continues beyond initial trial, evaluate appropriateness and dosing within 12 months after initiation 1
• For patients requiring chronic therapy without proven GERD, perform endoscopy with prolonged wireless reflux monitoring off medication to establish appropriateness of long-term use 1

Important Caveat About H2-Receptor Antagonists

• PPIs are significantly more effective than H2-receptor antagonists (like famotidine) for GERD treatment 3
• Famotidine may be used as adjunctive therapy for nocturnal symptoms only when personalized to the GERD phenotype 1
• Consider switching to a PPI if famotidine provides inadequate response after the initial trial period 1

Domperidone Duration

Critical Recommendation Against Use

• Domperidone should NOT be used for GERD treatment 3
• The American Gastroenterological Association provides a Grade D recommendation (recommend against): "fair evidence that it is ineffective or harms outweigh benefits" for metoclopramide (a similar prokinetic) as monotherapy or adjunctive therapy in GERD 3

Evidence Against Domperidone

• A 2019 randomized controlled trial showed no significant improvement in quality of life or symptoms when adding domperidone to PPI therapy in refractory GERD 4
• A pediatric study found domperidone was "only minimally effective" after 4 weeks and did not result in symptomatic improvement 5
• Prokinetic medications have not been proven to help in the control of GERD symptoms 6

When Prokinetics Might Be Considered

• If a prokinetic is absolutely necessary, it should be personalized to specific phenotypes: regurgitation-predominant or belch-predominant symptoms, or coexistent gastroparesis 1
• Even in these scenarios, baclofen is preferred over domperidone for regurgitation/belch symptoms 1
• Duration should be as short as possible given lack of long-term safety data and questionable efficacy

Practical Algorithm

Week 0-8:

• Use famotidine 20-40 mg twice daily (or preferably switch to PPI) 2
• Avoid domperidone entirely 3

Week 8-12:

• If symptoms controlled: taper to lowest effective dose 1
• If inadequate response: switch to PPI therapy 3
• Maximum famotidine trial duration: 12 weeks 2

Month 12:

• Reassess need for continued therapy 1
• Consider objective testing (endoscopy, pH monitoring) if therapy continues 1

Common Pitfall: Continuing H2-receptor antagonists like famotidine long-term when PPIs would be more effective, or adding domperidone empirically without evidence of gastroparesis or specific motility disorder 3, 1.